Apr. 21 at 5:40 PM
eXoZymes (Nasdaq:
$EXOZ ) CEO Michael Heltzen was featured on Session 20 of the GeneCoda podcast Executive Insights for Life Sciences Innovators, in an episode titled “AI-enabled cell-free biomanufacturing and the future of enzyme engineering,” streamed live on YouTube on April 17.
eXoZymes is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1.
In the conversation, Heltzen discusses the company’s thesis that producing complex molecules outside living cells can enable greater control, scalability, and speed compared to traditional biologic manufacturing. The discussion also covers how AI is helping identify and optimize enzyme pathways, the strategic considerations involved in building a platform company in today’s capital environment, what differentiates cell-free systems from established synthetic biology approaches, and where cell-free biomanufacturing could create commercial impact across nutraceutical, pharmaceutical, and industrial markets.
Watch or listen here: https://exozymes.com/blog/podcast-genecoda-2026
Separately, eXoZymes and Cayman Chemical were featured in a Springwise case study on how the two companies are rethinking chemical manufacturing. The piece focuses on eXoZymes’ work bringing enzyme pathways from biology into the world of chemistry, with Cayman Chemical helping to scale the approach. CCO Damien Perriman is featured in the article.
See the eXoZymes summary: https://exozymes.com/blog/springwise-2026
eXoZymes is a Los Angeles, California-based biotechnology company that has developed a biomanufacturing platform offering the tools and insights to design, engineer, control, and optimize nature’s own natural processes to produce highly valuable natural products via a commercially scalable, sustainable, and abundant alternative: exozymes.
eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff.
Learn more about eXoZymes Inc. at https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor and learn about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.
$DNLI,
$TWST,
$DNA,
$ARKG